| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 21, 2022 |
| Accession Number: | 0001193125-22-246467 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in development. He will be replacing Dr. Giuseppe Del Priore. “On behalf of the board of directors, we truly appreciate Giuseppe’s many contributions towards advancing our programs and we wish him continued success in his future endeavors,” said Richie Cunningham, TYME’s CEO. Dr. Van Tornout brings
15-12G - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
EFFECT - TYME TECHNOLOGIES, INC. (0001537917) (Filer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
4 - TYME TECHNOLOGIES, INC. (0001537917) (Issuer)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
SC 13G/A - TYME TECHNOLOGIES, INC. (0001537917) (Subject)
Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered into a definitive merger agreement pursuant to which Syros will acquire TYME, including its pipeline assets and net cash at closing which after accounting for wind-dow
– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing's and other sarcoma types – Pursuing options to diversify the clinical pipeline – Well-capitalized position, with $92.0 million in cash and marketable securities as of December 31, 2021 – Company to host live conference call and webcast today, February 11, at 8:30 AM ET TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emer
TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows: Date: Friday, February 11, 2022 Time: 8:30 AM ET Toll-free (U.S.) (866) 601-3896 International (636) 812-6499 Conference ID 1286376 The webcast will be accessible on the Events & Presentations page of the Investors s
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pu
-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" -- -- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the "Merger Agreement"), pursuant to which a direct, wholly owned subsidiary of Syros will merge with
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") have recommended that Tyme stockholders vote "FOR" the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. ("Syros") and "FOR" all other matters to be voted upon at the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for September 15, 2022 at 11:00 a.m., Eastern Time. ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide pro
Gainers Quotient (NASDAQ:QTNT) shares increased by 15.7% to $0.24 during Friday's pre-market session. The company's market cap stands at $32.5 million. Tyme Technologies (NASDAQ:TYME) stock moved upwards by 13.21% to $0.33. The market value of their outstanding shares is at $56.0 million. Landos Biopharma (NASDAQ:LABP) shares increased by 10.47% to $1.16. The company's market cap stands at $46.6 million. Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 9.06% to $1.34. The company's market cap stands at $41.4 million. Addex Therapeutics (NASDAQ:ADXN) shares rose 8.84% to $1.04. The market value of their outstanding shares is at $8.5 million. 9 Meters Biopharma (NASDAQ:
Gainers Kensington Capital Acquisition Corp. IV (NYSE:AMPX) rose 159.4% to $25.94 in pre-market trading after gaining 11% on Thursday. Applied Optoelectronics, Inc. (NASDAQ:AAOI) shares rose 31.2% to $3.28 in pre-market trading after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million. Fast Radius, Inc. (NASDAQ:FSRD) rose 11.1% to $0.5711 in pre-market trading. Fast Radius, last month, posted a Q2 loss of $0.29 per share. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) rose 11.7% to $0.8149 in pre-market trading after the company and Tyme Technologies announced stockholder approval of the merger agreement. The company a
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Friday after recording losses on Thursday. The Nasdaq 100 index dipped more than 200 points in the previous session following the release of several economic reports. The University of Michigan's consumer sentiment report for September is scheduled for release at 10:00 a.m. ET. After rising around 7 points in August, analysts expect consumer sentiment improving further by 1.7 points to 59.9 in September. Check out this: Volatility In Markets Increases As Nasdaq Tumbles 200 Points Futures for the Dow Jones Industrial Average dipped 262 points to 30,712.00 while the Standard & Poor’s 500 index futures fell 37 poi